Additional file 2: of Economic evaluation of trimetazidine in the management of chronic stable angina in Greece

Drug acquisition cost. Data description: Proportion of patients using each therapy, mean drug daily dose and relative drug acquisition cost is presented in the file. (DOCX 70 kb

Additional file 1: of Economic evaluation of trimetazidine in the management of chronic stable angina in Greece

Questionnaire. Data description: The questionnaire used to collect data from local Key Opinion Leaders is presented in the file. (DOCX 65 kb

Additional file 1: Table S1. of Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study

Drug acquisition cost considered in the model. (DOCX 79 kb

MOESM1 of Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema

Additional file 1. Transition probabilities

A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences

<p></p><p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-018-0759-0">here</a><b>.</b> </p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p><br><p></p